RxDoctor Payments Data

Robert Elliott, MD

Family Medicine · Hurt, VANPI 1669454344

Payments from drug & device makers

$1,220in general payments, 2019–2025

Across 12 payments — averaging $101.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$1K
  • Xeris Pharmaceuticals, Inc.$47
  • Novo Nordisk$35
  • Inspire Medical Systems, Inc.$15
  • AstraZeneca$13
  • Pfizer$11

What the payments were for

  • Travel & lodging$69257%
  • Food & beverage$52843%

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,220 in reported general payments places this provider in the 70th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$221,857
Medicare patients
400
Services billed
9,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$114,313
EliquisApixaban112$100,287
JardianceEmpagliflozin102$84,588
MounjaroTirzepatide32$46,314
FarxigaDapagliflozin Propanediol48$46,264
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$33,227
XareltoRivaroxaban42$31,437
RybelsusSemaglutide19$30,896
TrulicityDulaglutide29$30,444
Breo ElliptaFluticasone/Vilanterol21$14,479
SymbicortBudesonide/Formoterol Fumarate32$11,017
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$8,917
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$7,865
Spiriva RespimatTiotropium Bromide12$6,218
Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm16$5,788

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$35$145,208118 claims
PfizerEliquis$11$100,287112 claims
AstraZenecaFarxiga, Symbicort$13$57,28180 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Hurt

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →